Amneal Pharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
306 | 57.86 | 428.9% | 15.72 | +1 846.13% |
| P/S |
|
0.4239 | 4.06 | -89.57% |
|
|
| P/BV |
|
50.7 | 9.39 | 439.84% |
|
|
| P/FCF |
|
2.08 | 46.57 | -95.53% |
|
|
| Ev/Ebitda |
|
8.79 | 17.55 | -49.92% |
|
|
| Ev/S |
|
1.53 | 4.36 | -64.77% |
|
|
| Ev/FCF |
|
13.29 | 54.43 | -75.58% |
|
|
| E/P |
|
-0.146 | 0.2164 | -167.46% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
5/10
|
17.46 | 20.15 | -13.33% | 13.29 | +31.39% |
| ROE |
|
-424.61 | -80.86 | 425.15% |
|
|
| ROA |
|
-2.42 | 6.71 | -136.02% |
|
|
| ROIC |
|
2.56 | 15.68 | -83.67% |
|
|
| ROS |
|
-3.51 | 10.56 | -133.25% |
|
|
| ROCE |
|
942.3 | 18.05 | 5120.16% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
0/10
|
6.35 | 2.82 | 125.6% | 9 | -29.41% |
| Nеt Debt/Ebitda |
|
6.36 | 3.64 | 74.92% |
|
|
| Debt/Ratio |
|
0.7646 | 0.261 | 192.94% |
|
|
| Debt/Equity |
|
5.65 | 4.81 | 17.58% |
|
|
| Debt/Net Income |
|
-31.61 | 6.35 | -597.94% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.29 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 6.33 | -100% | ||
| DSI |
|
0 | 0.7376 | -100% |
|
|
| Average dividend growth |
|
0 | -3.12 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.29 | -100% |
|
|
| Average percentage for payments |
|
152.57 | 77.61 | 96.58% |
|
|
| Difference from average difference in sector |
|
-1.29 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
6/10
|
46.85 | 362.86 | -87.09% | ||
| Growth impulse Ebitda in 5 years |
|
472.72 | 373.75 | 26.48% | ||
| Growth impulse Net Income in 5 years |
|
-86.08 | 454.84 | -118.93% | ||
| Growth impulse FCF in 5 years |
|
-388.81 | 306.17 | -226.99% | ||
| Growth impulse EPS in 5 years |
|
-89.57 | 455.99 | -119.64% |
IP Score
3.32/10
